OncoCyte Yönetim

Yönetim kriter kontrolleri 1/4

OncoCyte CEO'su Josh Riggs, Dec2022 tarihinde atandı, in görev süresi 1.92 yıldır. in toplam yıllık tazminatı $ 724.91K olup, şirket hissesi ve opsiyonları dahil olmak üzere 46.9% maaş ve 53.1% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.021% ine doğrudan sahiptir ve bu hisseler $ 8.55K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 1.7 yıl ve 3.8 yıldır.

Anahtar bilgiler

Josh Riggs

İcra Kurulu Başkanı

US$724.9k

Toplam tazminat

CEO maaş yüzdesi	46.9%
CEO görev süresi	1.9yrs
CEO sahipliği	0.02%
Yönetim ortalama görev süresi	1.7yrs
Yönetim Kurulu ortalama görev süresi	3.8yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Josh Riggs'un ücretlendirmesi OncoCyte'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$44m
Jun 30 2024	n/a	n/a	-US$37m
Mar 31 2024	n/a	n/a	-US$40m
Dec 31 2023	US$725k	US$340k	-US$26m
Sep 30 2023	n/a	n/a	-US$22m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$11m
Dec 31 2022	US$514k	US$242k	-US$19m

Tazminat ve Piyasa: Josh 'nin toplam tazminatı ($USD 724.91K ), UK pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 358.05K ).

Tazminat ve Kazançlar: Josh şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Josh Riggs (41 yo)

1.9yrs

Görev süresi

US$724,910

Tazminat

Mr. Joshua Riggs, also known as Josh, serves as Director of OncoCyte Corporation since February 28, 2023, serves as its Chief Executive Officer & President since February 24, 2023. He served as Interim Chi...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Riggs	President	1.9yrs	US$724.91k	0.021% $ 8.6k
James Liu	Senior Director	2.2yrs	US$304.51k	0% $ 0
Ekkehard Schutz	Chief Science Officer	1.8yrs	US$575.17k	0.030% $ 12.4k
Andrea James	Chief Financial Officer	less than a year	Veri yok	0.20% $ 82.2k
Yuh-Min Chiang	Chief Technology Officer	1.5yrs	Veri yok	Veri yok
Peter Hong	VP, General Counsel & Secretary	less than a year	Veri yok	Veri yok
Sandra O'Donald	Senior Vice President of Business Operations	1.3yrs	Veri yok	Veri yok
Michael West	Scientific Advisor	9.1yrs	US$328.84k	Veri yok

1.7yrs

Ortalama Görev Süresi

41yo

Ortalama Yaş

Deneyimli Yönetim: 0KCC 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 1.7 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Joshua Riggs	President	1.8yrs	US$724.91k	0.021% $ 8.6k
Louis Silverman	Lead Independent Director	2yrs	US$97.70k	0.0093% $ 3.8k
Andrew Arno	Independent Chairman	9.4yrs	US$112.54k	0.50% $ 206.6k
Daniel Hayes	Member of Scientific & Medical Advisory Board	3.8yrs	Veri yok	Veri yok
David R. Gandara	Member of Scientific & Medical Advisory Board	no data	Veri yok	Veri yok
Robert Ferris	Member of Scientific & Medical Advisory Board	no data	Veri yok	Veri yok
John Kirkwood	Member of Scientific & Medical Advisory Board	3.8yrs	Veri yok	Veri yok
Andrew Last	Independent Director	8.9yrs	US$92.86k	0.027% $ 11.0k
Fred Hirsch	Member of Scientific & Medical Advisory Board	3.8yrs	Veri yok	Veri yok
Heinz-Josef Lenz	Member of Scientific & Medical Advisory Board	3.8yrs	Veri yok	Veri yok
Ignacio Wistuba	Member of Scientific & Medical Advisory Board	3.8yrs	Veri yok	Veri yok

3.8yrs

Ortalama Görev Süresi

64.5yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 0KCC 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.8 yıldır).

OncoCyte Yönetim

Yönetim kriter kontrolleri 1/4

Anahtar bilgiler

Son yönetim güncellemeleri

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

Oncocyte Corporation Announces Executive Changes

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

High number of new and inexperienced directors

Recent updates

OncoCyte Corporation to Report Q3, 2024 Results on Nov 12, 2024

Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

OncoCyte Corporation announced that it expects to receive $10.203435 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $0.316184 million.

OncoCyte Corporation has filed a Follow-on Equity Offering in the amount of $7.5 million.

OncoCyte Corporation to Report Q2, 2024 Results on Aug 08, 2024

Oncocyte Announces Notice of Prior Non-Compliance and Subsequent Compliance with Nasdaq Listing Rules 5605(b)(1) and 5605(c)(2)

OncoCyte Corporation announced that it expects to receive $3.5 million in funding from Bio-Rad Laboratories, Inc.

OncoCyte Corporation Appoints Andrea James as Chief Financial Officer

Oncocyte Corporation Announces Promising Results in A Phase 2 Clinical Trial

Oncocyte Corporation Announces Favorable Oncocyte Vitgraft Kidney Study Results

OncoCyte Corporation to Report Q1, 2024 Results on May 15, 2024

OncoCyte Corporation, Annual General Meeting, Jun 28, 2024

OncoCyte Corporation announced that it has received $15.8 million in funding

Broadwood Capital, Inc. Engages with OncoCyte Corporation

OncoCyte Corporation announced that it expects to receive $15.8 million in funding

OncoCyte Corporation announced delayed annual 10-K filing

OncoCyte Corporation announced delayed annual 10-K filing

Oncocyte Corporation Begins FDA Submissions Process for VitaGraft Transplant Assays

OncoCyte Corporation to Report Q3, 2023 Results on Nov 09, 2023

Oncocyte Corporation Announces Vitagraft Kidney Transplant Diagnostic Test Receives Cms Coverage

Oncocyte Corporation Announces Executive Changes

OncoCyte Regains Compliance with Nasdaq Listing Requirements

OncoCyte Corporation to Report Q2, 2023 Results on Aug 10, 2023

Oncocyte Corporation Announces the Publication of New Data Demonstrating Vitagraft Kidney's Novel Ability to Help Physicians Treat Kidney Transplant Patients

Oncocyte Announces 1-For-20 Reverse Stock Split to Regain Compliance with Minimum Bid Price Requirement

Jennifer Levin Carter and John Peter Gutfreund Not to Stand for Re-Election to the Board of Directors of OncoCyte Corporation

OncoCyte Corporation, Annual General Meeting, Jun 23, 2023

OncoCyte Receives Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard

Oncocyte Applies to Transfer the Listing of its Common Stock from The Nasdaq Global Market to The Nasdaq Capital Market

OncoCyte Corporation Announces Reduction of Workforce

High number of new and inexperienced directors

OncoCyte Corporation Announces Executive Changes

Melinda Griffith Notifies Oncocyte Corporation F Her Resignation from the Board, Effective January 1, 2023

OncoCyte Corporation to Report Q3, 2022 Results on Nov 10, 2022

High number of new directors

Oncocyte Corporation Appoints James Liu as Controller and Principal Accounting Officer

High number of new directors

Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on Determarx to CMS

Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer

Independent Chairman recently bought US$144k worth of stock

OncoCyte Corporation Receives Non-Compliance Letter from Nasdaq

Second quarter 2022 earnings released: US$0.073 loss per share (vs US$0.12 loss in 2Q 2021)

OncoCyte Corporation Appoints Anish John as Chief Financial Officer

OncoCyte Corporation Announces the Appointment of John Peter Gutfreund as Independent Member of its Board of Directors

OncoCyte Corporation to Report Q2, 2022 Results on Aug 10, 2022

High number of new directors

OncoCyte Corporation Announces Resignation of Li Yu as Controller and Principal Accounting Officer

OncoCyte Corporation(NasdaqGM:OCX) dropped from Russell 2000 Dynamic Index

OncoCyte Corporation, Annual General Meeting, Jul 15, 2022

First quarter 2022 earnings released: US$0.11 loss per share (vs US$0.048 loss in 1Q 2021)

Oncocyte Corporation Completes Validation of TheraSure™ Transplant Monitor Test

High number of new directors

Broadwood Capital Engages in Discussions with OncoCyte Corporation

OncoCyte Corporation has completed a Follow-on Equity Offering in the amount of $35.000001 million.

High number of new directors

OncoCyte Corporation to Report Q4, 2021 Results on Mar 10, 2022

OncoCyte Corporation Announces Peer-Reviewed Publication in Cancers Showing Utility of DetermaCNI™ Blood-Only Monitoring Test to Detect Recurrence Following Surgery in Epithelial Ovarian Cancer

Oncocyte Corporation Announces Results from DetermaIO™ Test

Third quarter 2021 earnings released: US$0.15 loss per share (vs US$0.10 loss in 3Q 2020)

High number of new directors

Broadwood Partners Engages in Discussions with OncoCyte Corporation

Oncocyte Corporation Announces Oral Presentation of New Data on Its DetermaIO Immunotherapy Response Test at the European Society for Medical Oncology Annual Meeting

Oncocyte Corporation Launches Nationwide, Prospective, Real-World Registry for Patients with Potentially Curable Early-Stage Lung Cancer

Second quarter 2021 earnings released: US$0.12 loss per share (vs US$0.14 loss in 2Q 2020)

High number of new directors

CEO, President & Director recently bought US$53k worth of stock

OncoCyte Corporation Announces Peer-Reviewed Publication of Data Assessing Use of DetermaIO™ to Identify Patients Likely to Benefit from Immunotherapy Across Multiple Tumor Types

Oncocyte Corporation Announces Formation of Medical Advisory Board